Fragile X syndrome: Clinical, cytogenetic and molecular screening among autism spectrum disorder children in indonesia

Clinical Genetics

Volumn 84, Issue 6, 2013, Pages 577-580

  Winarni, T I ^a   Utari, A ^a   Mundhofir, F E P ^a   Hagerman, R J ^b   Faradz, S M H ^a  

^a DIPONEGORO UNIVERSITY   (Indonesia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism spectrum disorders; FMR1 screening; Fragile X site; Fragile X syndrome; Indonesia

Indexed keywords

ADOLESCENT; ALLELE; ARTICLE; AUTISM; CHILD; CHILDHOOD AUTISM RATING SCALE; CLINICAL FEATURE; CYTOGENETICS; DISEASE SEVERITY; DSM-IV-TR; FEMALE; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE MUTATION; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SCREENING; SOUTHERN BLOTTING;

AUTISM SPECTRUM DISORDERS; FMR1 SCREENING; FRAGILE X SITE; FRAGILE X SYNDROME; INDONESIA;

ABNORMAL KARYOTYPE; ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CYTOGENETIC ANALYSIS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC TESTING; HUMANS; INDONESIA; MALE; MUTATION; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 84886771359     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12095     Document Type: Article

References (47)

1. Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006: 117: 1028-1037.
2. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. Prevalence of autism in a United States population: the brick township, New Jersey, investigation. Pediatrics 2001: 108: 1155-1161.
3. Autism Developmental Disabilities Monitoring Network. Prevalence of autism spectrum disorders (ASDs) among multiple areas of the United States in 2008. In: Baio J, ed. Atlanta: centers for disease control and prevention. Atlanta, GA: U.S. Department of Health and Human Services, 2012: 1-40.
4. Hagerman PJ. The fragile X prevalence paradox. J Med Genet 2008: 45: 498-499.
5. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009: 11: 324-329.
6. Crawford DC, Meadows KL, Newman JL et al. Prevalence of the fragile X syndrome in African-Americans. Am J Med Genet 2002: 110: 226-233.
7. Song FJ, Barton P, Sleightholme V, Yao GL, Fry-Smith A. Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 2003: 7: 1-106.
8. Hagerman RJ, Chudley AE, Knoll JH, Jackson AW 3rd, Kemper M, Ahmad R. Autism in fragile X females. Am J Med Genet 1986: 23: 375-380.
9. Hagerman RJ, Jackson AW, Levitas A, Rimland B, Braden M. An analysis of autism in fifty males with the fragile X syndrome. Am J Med Genet 1986: 23: 359-374.
10. Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord 2011: 3: 57-67.
11. Harris SW, Hessl D, Goodlin-Jones B et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008: 113: 427-438.
12. Kover ST, Abbeduto L. Expressive language in male adolescents with fragile X syndrome with and without comorbid autism. J Intellect Disabil Res 2010: 54: 246-265.
13. Philofsky A, Hepburn SL, Hayes A, Hagerman RJ, Rogers SJ. Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome. Am J Ment Retard 2004: 109: 208-218.
14. Bailey DB Jr, Hatton DD, Mesibov GB, Ament N, Skinner M. Early development, temperament and functional impairment in autism and fragile X syndrome. J Autism Dev Disord 2000: 30: 49-59.
15. Zingerevich C, Greiss-Hess L, Lemons-Chitwood K et al. Motor abilities of children diagnosed with fragile X syndrome with and without autism. J Intellect Disabil Res 2009: 53: 11-18.
16. Reddy KS. Cytogenetic abnormalities and fragile-X syndrome in autism spectrum disorder. BMC Med Genet 2005: 6: 3.
17. Wassink TH, Piven J, Patil SR. Chromosomal abnormalities in a clinic sample of individuals with autistic disorder. Psychiatr Genet 2001: 11: 57-63.
18. Rousseau F, Labelle Y, Bussieres J, Lindsay C. The fragile x mental retardation syndrome 20years after the FMR1 gene discovery: an expanding universe of knowledge. Clin Biochem Rev 2011: 32: 135-162.
19. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci 2006: 9: 1221-1225.
20. Hagerman R, Hoem G, Hagerman P. Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 2010: 1: 12.
21. Chugani DC. Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 2002: 7 (Suppl. 2): S16-S17.
22. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. In: Denman RB, ed. Modeling fragile X syndrome. Berlin; Heidelberg: Springer-Verlag, 2012: 297-335.
23. Silverman JL, Smith DG, Rizzo SJ et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 2012: 4: 131ra51.
24. Winarni TI, Chonchaiya W, Adams E et al. Sertraline may improve language developmental trajectory in young children with fragile x syndrome: a retrospective chart review. Autism Res Treat 2012: 2012: 8pages.
25. DeLong GR, Ritch CR, Burch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 2002: 44: 652-659.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition-text revised. Washington DC: American Psychiatric Association, 2000.
27. Schopler E, Reichler R, DeVellis R, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 1980: 10: 91-103.
28. Perry A, Condillac R, Freeman N, Dunn-Geier J, Belair J. Multi-site study of the Childhood Autism Rating Scale (CARS) in five clinical groups of young children. J Autism Dev Disord 2005: 35: 625-634.
29. Sutherland GR. Heritable fragile sites on human chromosomes I. Factors affecting expression in lymphocyte culture. Am J Hum Genet 1979: 31: 125-135.
30. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988: 16: 1215.
31. Fu Y-H, Kuhl DPA, Pizzuti A et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991: 67: 1047-1058.
32. Miles JH, Takahashi TN, Bagby S et al. Essential versus complex autism: definition of fundamental prognostic subtypes. Am J Med Genet A 2005: 135: 171-180.
33. Cantu ES, Jacobs PA. Fragile (X) expression: relationship to the cell cycle. Hum Genet 1984: 67: 99-102.
34. Mizuochi T, Kimura A, Ueki I et al. Molecular genetic and bile acid profiles in 2 Japanese patients with 3beta-hydroxy-delta5-C27-steroid dehydrogenase/isomerase deficiency. Pediatr Res 2010: 68: 258-263.
35. Hecht F, Sutherland GR. Detection of the fragile X chromosome and other fragile sites. Clin Genet 1984: 26: 301-303.
36. Wang Q, Green E, Barnicoat A et al. Cytogenetic versus DNA diagnosis in routine referrals for fragile X syndrome [see comments]. Lancet 1993: 342: 1025-1026.
37. Bhowmik DA, Dutta A, Chatterjee A, Sinha AK, Chattopadhyay A, Mukhopadhyay K. Screening for fragile X syndrome among neurobehavioral patients from Kolkata, Eastern India. J Clin Diagn Res 2009: 3: 1266-1273.
38. Kaufmann WE, Cortell R, Kau AS et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet 2004: 129A: 225-234.
39. Bukelis I, Porter FD, Zimmerman AW, Tierney E. Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry 2007: 164: 1655-1661.
40. Veltman MW, Craig EE, Bolton PF. Autism spectrum disorders in Prader-Willi and Angelman syndromes: a systematic review. Psychiatr Genet 2005: 15: 243-254.
41. Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord 1998: 28: 407-414.
42. Iossifov I, Ronemus M, Levy D et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012: 74: 285-299.
43. Hernandez RN, Feinberg RL, Vaurio R, Passanante NM, Thompson RE, Kaufmann WE. Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation. Am J Med Genet A 2009: 149A: 1125-1137.
44. Smith LE, Barker ET, Seltzer MM, Abbeduto L, Greenberg JS. Behavioral phenotype of fragile X syndrome in adolescence and adulthood. Am J Intellect Dev Disabil 2012: 117: 1-17.
45. Jacquemont S, Curie A, des Portes V et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011: 3: 64ra1.
46. Berry-Kravis EM, Hessl D, Rathmell B et al. Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012: 4: 152ra127.
47. Gurkan CK, Hagerman RJ. Targeted treatments in autism and fragile X syndrome. Res Autism Spectr Disord 2012: 6: 1311-1320.